Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certification & Accreditation
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients
By
- AMS
posted
Jul 07, 2020 12:13 PM
0
Recommend
.
0 comments
0 views
Related Content
The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients
- AMS
Added Jun 02, 2020
Blog Entry
Management strategies of autoimmune bullous diseases during the outbreak of 2019 Novel Coronavirus disease (COVID-19)
- AMS
Added Jun 01, 2020
Blog Entry
Case Study: Periorbital Rejuvenation with Thermonmechanical Therapy
- AMS
Added Oct 06, 2021
Blog Entry
Vitamin D status in patients with autoimmune bullous dermatoses: a meta-analysis
- AMS
Added Aug 27, 2020
Blog Entry
Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review
- AMS
Added Apr 21, 2020
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic